Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2899064 | 0.77 | CYP3A4 (0.40) | TSHRHSD17B10CYP1A2ALDH1A1USP2 | |
| SCHEMBL604857 | 0.69 | SLC6A3 (0.40) | HTR1AHTR2ATSHRHSD17B10HTR3E | |
| SCHEMBL604859 | 0.69 | SLC6A3 (0.40) | HTR1AHTR2ATSHRHSD17B10HTR3E | |
| SCHEMBL2008409 | 0.66 | SLC6A3 (0.39) | AVPR1AKDM4ELMNAPOLBNR4A1 | |
| SCHEMBL5234760 | 0.65 | USP2 (0.56) | HTR1AHTR2ATSHRHSD17B10HTR3E | |
| SCHEMBL8112531 | 0.64 | AKR1C1 (0.52) | NR4A1NR4A2NR4A3CDC25B | |
| SCHEMBL5067826 | 0.64 | MEN1 (0.46) | TSHRCYP2D6SIGMAR1ALDH1A1KMT2A | |
| SCHEMBL1876619 | 0.63 | NCF1 (0.69) | HTR1AHTR2ATSHRHSD17B10HTR3E | |
| SCHEMBL569714 | 0.63 | HTR1A (0.69) | HTR1AHTR2ATSHRHSD17B10HTR3E | |
| SCHEMBL2494142 | 0.63 | SLC6A3 (0.40) | AVPR1ASIGMAR1KDM4ELMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7732451-B2 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7718802-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7709484-B1 | Substituted melanocortin receptor-specific piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7655658-B2 | Use of in the treatment of melanocortin receptor-associated disorders such as in treatment of anorexia, as a weight gain aid, for treatment of obesity | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2009144432-A1 | MC4-R AGONISTS FOR THE TREATMENT OF OBESITY | PALATIN TECHNOLOGIES, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-7601753-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090076029-A1 | Compounds and Methods for Treating Obesity | PALATIN TECHNOLOGIES, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20070155670-A1 | Pyrrolidine Melanocortin-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7189755-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1622618-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | Palatin Technologies, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005102340-A1 | PIPERAZINE MELANOCORTIN-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-20050130988-A1 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2005-06-16 | — | — | US | disclosed |
| US-20050124636-A1 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130988-A1 | Naphthalene-containing melanocortin receptor-specific small molecule | MC1R, MC3R, MC2R | AVPR1A 23/4885HTR1A 263/4885HTR2A 452/4885 |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | MC3R, MC1R, MC5R | AVPR1A 18/4885HTR1A 43/4885HTR2A 70/4885 |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | MC1R, MC5R, MC3R | AVPR1A 45/4885HTR1A 44/4885HTR2A 26/4885 |
| US-20090076029-A1 | Compounds and Methods for Treating Obesity | MC4R, MC3R, MC1R | AVPR1A 166/4885HTR1A 164/4885HTR2A 186/4885 |
| US-20070155670-A1 | Pyrrolidine Melanocortin-Specific Compounds | MC3R, MC1R, MC5R | AVPR1A 18/4885HTR1A 61/4885HTR2A 78/4885 |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PDE3B, PDE3A, PDE5A | AVPR1A 57/4885HTR1A 862/4885HTR2A 1078/4885 |
| US-20050124636-A1 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds | MC1R, MC5R, MC4R | AVPR1A 64/4885HTR1A 47/4885HTR2A 51/4885 |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | MC3R, MC4R, MC1R | AVPR1A 86/4885HTR1A 245/4885HTR2A 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.